New Jersey Law Journal – Merck must hand over internal documents related to its valuation of an osteoporosis drug it developed, thanks to a New Jersey federal judge’s decision.
In Biotechnology Value Fund v. Celera, U.S. Magistrate Judge Douglas Arpert of the District of New Jersey on Aug. 28 granted a motion to compel compliance with a third-party subpoena issued months ago to Merck by plaintiff Biotechnology Value Fund.
